Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT06348576
PHASE3
Phase III Study to Evaluate the Efficacy and Safety of AD-209
Sponsor: Addpharma Inc.
View on ClinicalTrials.gov
Summary
The purpose of this study is to evaluate the efficacy and safety of AD-209
Official title: A Multicenter, Randomized, Double-blind, Active-control, Phase III Study to Evaluate the Efficacy and Safety of AD-209 in Patients With Essential Hypertension
Key Details
Gender
All
Age Range
19 Years - Any
Study Type
INTERVENTIONAL
Enrollment
280
Start Date
2024-05-20
Completion Date
2025-02
Last Updated
2024-05-21
Healthy Volunteers
No
Conditions
Interventions
DRUG
AD-209
PO, Once daily(QD), 8weeks
DRUG
AD-2091
PO, Once daily(QD), 8weeks
DRUG
AD-209 Placebo
PO, Once daily(QD), 8weeks
DRUG
AD-2091 Placebo
PO, Once daily(QD), 8weeks
Locations (1)
Korea University Guro Hospital
Seoul, South Korea